High-Risk Localized Prostate Cancer to be eliminated by Abiraterone Acetate

May 25, 2012 by  
Filed under Prostate Cancer News

Findings from a second phase clinical trial indicates that a combintation of a new prostate cancer drug — Abiraterone Acetate  (Zytiga)– with prednisone and surgery can eliminate  high risk prostate cancer. This type of cancer is still residing within the prostate cells but it is still is on the verge of being metastasized to other parts of the body.

The clinical trial was conducted on men with localized high-risk prostate cancer, and which were given a combination of the three treatments. Significant results to conclude on the efficacy of the treatments were made. Details on this clinical trial are provided below:

Men with prostate cancer could significantly benefit from a recently approved hormone-depleting drug, according to results from a phase II clinical trial.

The drug – abiraterone acetate (Zytiga(R)) – can help eliminate or almost eliminate tumors in many prostate cancer patients whose cancer has not yet metastasized.

The study, conducted by researchers at Dana-Farber Cancer Institute in collaboration with other research centers, will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), June 1-5, in Chicago.

In order to examine the effects of (Zytiga(R)) in combination with prednisone and surgery, the researchers enrolled 58 men with high-risk prostate cancer isolated to the prostate gland to participate in the study.

Study participants were assigned to receive the combination therapy for either three or six months, in addition to surgery to remove the prostate. After completing the treatment regimen, the researchers found that one-third of the men had either little or no tumor tissue left.

Mary-Ellen Taplin, M.D., of Dana-Farber, and lead author of the study, said:

“Very high-risk cancers localized to the prostate are rarely cured by prostatectomy alone. Therapies that combine surgery with older androgen-inhibiting drugs have not historically improved outcomes. This unmet need has given rise to efforts to develop new drugs capable of more completely reducing androgen levels within the prostate tumors.”

The male hormone androgen powers prostate cancer growth, and although standard treatments target the production of this hormone in the adrenal glands and testes, they do not target androgen within the tumor itself. However, abiraterone acetate has the ability to inhibit the production of androgen in all three sites.

In addition to abiraterone acetate, study participants also received 5mg daily of prednisone (a steroid). Conventionally, prednisone is administered with abiraterone acetate in a 10mg dose. However, the researchers believed that the lower dose would reduce the adverse effects of prednisone while maintaining its benefits. According to the researchers, the 5mg dose is adequate for the majority of patients.

Taplin explained:

“Most of the patients in this study had large tumors, high grade prostate cancers and were at high risk for cancer spread. We’re very encouraged by the results and have begun another phase II study investigating another novel androgen signaling inhibitor, MDV3100, in the neoadjuvant setting for high risk prostate cancer.

We are also developing a clinical trial program investigating the addition of the investigational drug ARN509 to abiraterone. To prove the overall benefit of intensive androgen deprivation treatment in conjunction with prostatectomy, a large randomized clinical trial will need to be done.”  Source.

This is good news for prostate cancer research and treatment. If the study of this study is validated after submissions to the American Society of Clinical Oncology (ASCO) in June, then a new way of treating localized but aggressive prostate cancer effectively would have been discovered.

Abiraterone Acetate is known to be effective in suppressing androgen in testes, the prostate and the cancer cells, as it is combined with Prednisone and surgery, prostate malignant tumor can be treated.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)

  1. High – Intensity Focused Ultrasound Is Safe and Effective for Localized Prostate Cancer
  2. New Miracle Drugs to Cure Prostate Cancer – Abiraterone
  3. Zytiga (Abiraterone) Can Stop Prostate Cancer Before Surgery
  4. Understanding the Drugs for Prostate Cancer Treatment
  5. Two New Prostate Cancer Drugs Can Extend Life For Men If Combined
  6. P53 Nfkb In Prostate Cancer – Low-Fat High-Fiber Diet And Exercise
  7. Vitamin E Increases Prostate Cancer Risk? New Study Thinks So.
  8. Bone Metastasis Prostate Cancer – Why You Should Be Worried
  9. Prostate Cancer Treatment – High Intensity Focused Ultrasound (HIFU)
  10. Cancer Hormone Prostate Refractory and Chemotherapy for Hormonal Refractory Prostate Cancer
  11. Prostate Cancer Risk Calculator Now Available Online

Speak Your Mind

Tell us what you're thinking... !